Healthcare is one of the most challenging M&A sectors to navigate because of the rise of new immunotherapy drugs and biosimilars, the emergence of Amazon and other potential distribution disruptors, and changing political dynamics like U.S. public opinion shifting toward single-payer healthcare. Encouragingly, 70% of Merrill Insight™ Healthcare M&A Spotlight’s viewers expressed confidence in the M&A market for the next 12 months. This interactive toolkit provides you with the insights on critical topics in Healthcare M&A.